CLINICAL TRIALS PROFILE FOR ARFORMOTEROL TARTRATE

All Clinical Trials for ARFORMOTEROL TARTRATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00250679 ↗	Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease	Completed	Sunovion	Phase 3	2005-10-01	To evaluate the long-term safety and monitor the long-term efficacy of arformoterol over a period of 6 months in subjects with chronic obstructive pulmonary disease (COPD).
NCT00424528 ↗	Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)	Completed	Sunovion	Phase 4	2006-12-01	The purpose of this study is to evaluate and compare the efficacy of arformoterol twice a day and tiotropium once a day (dosed sequentially) versus tiotropium once a day alone in subjects with Chronic Obstructive Pulmonary Disease (COPD).
NCT00571428 ↗	Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD	Completed	Sunovion	Phase 4	2007-11-01	To evaluate the efficacy and safety of arformoterol tartrate inhalation solution 30μg/4mL QD (two 15μg/2mL dosed in combination) over a 24-hour period compared to arformoterol tartrate inhalation solution 15μg/2 mL BID in subjects with COPD.
NCT00583947 ↗	A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects	Completed	Sunovion	Phase 2	2008-01-01	To determine the safety and tolerability of Arformoterol Tartrate in children with asthma
NCT00685529 ↗	Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)	Completed	Sunovion	Phase 2	2005-04-01	The purpose of this study is to compare the blood levels of arformoterol tartrate inhalation solution to racemic formoterol in male and female subjects with mild to moderate Chronic Obstructive Pulmonary Disease (COPD).
NCT00754546 ↗	Effect of Bronchodilation on Cycle vs Treadmill Exercise Endurance Time in COPD	Completed	Sunovion	Phase 4	2008-08-01	Previous studies suggest that treadmill exercise may be a more relevant exercise stimulus than the cycle ergometer to demonstrate benefits with bronchodilator therapy in patients with COPD. The hypothesis of the study is that patients with COPD will exhibit greater improvements in exercise endurance and breathlessness with arformoterol compared with normal saline during treadmill walking than with cycle exercise.

Clinical Trial Conditions for ARFORMOTEROL TARTRATE

Condition Name

Condition Name for ARFORMOTEROL TARTRATE
Intervention	Trials
Chronic Obstructive Pulmonary Disease	6
Emphysema	3
COPD	2
Bronchitis	2

Condition MeSH

Condition MeSH for ARFORMOTEROL TARTRATE
Intervention	Trials
Pulmonary Disease, Chronic Obstructive	8
Lung Diseases, Obstructive	8
Lung Diseases	8
Bronchitis	3

Clinical Trial Locations for ARFORMOTEROL TARTRATE

Trials by Country

Trials by Country for ARFORMOTEROL TARTRATE
Location	Trials
United States	105

Trials by US State

Trials by US State for ARFORMOTEROL TARTRATE
Location	Trials
South Carolina	7
California	6
Oregon	5
North Carolina	5
Florida	5

Clinical Trial Progress for ARFORMOTEROL TARTRATE

Clinical Trial Phase

Clinical Trial Phase for ARFORMOTEROL TARTRATE
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	2
Phase 2	2

Clinical Trial Status

Clinical Trial Status for ARFORMOTEROL TARTRATE
Clinical Trial Phase	Trials
Completed	7
Unknown status	1
Terminated	1

Clinical Trial Sponsors for ARFORMOTEROL TARTRATE

Sponsor Name

Sponsor Name for ARFORMOTEROL TARTRATE
Sponsor	Trials
Sunovion	9
Dartmouth-Hitchcock Medical Center	1
University of California, Los Angeles	1

Sponsor Type

Sponsor Type for ARFORMOTEROL TARTRATE
Sponsor	Trials
Industry	9
Other	2